740MO Dostarlimab + chemotherapy for the treatment of primary advanced or recurrent endometrial cancer (pA/rEC): Analysis of progression free survival (PFS) and overall survival (OS) outcomes by molecular classification in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial-Reference-Cited by-同舟云学术

740MO Dostarlimab + chemotherapy for the treatment of primary advanced or recurrent endometrial cancer (pA/rEC): Analysis of progression free survival (PFS) and overall survival (OS) outcomes by molecular classification in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial

Published:2023-10 Issue: Volume:34 Page:S507
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Mirza M.R.,Sharma S.,Herrstedt J.,Shahin M.S.,Cibula D.,Fleming E.,Raspagliesi F.,Buscema J.,Hanker L.C.,Coleman R.L.,Boere I.A.,Schneider K.,Gilbert L.,Slomovitz B.M.,Teneriello M.G.,Powell M.A.,Ghosh S.,Stevens S.,Ring K.,Stuckey A.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Atezolizumab and chemotherapy for advanced or recurrent endometrial cancer (AtTEnd): a randomised, double-blind, placebo-controlled, phase 3 trial;The Lancet Oncology;2024-09

2. Efficacy of immune-checkpoint inhibitors combined with cytotoxic chemotherapy in advanced or recurrent endometrial cancer: A systematic review and meta-analysis;Gynecologic Oncology;2024-08

3. Tailoring Endometrial Cancer Treatment Based on Molecular Pathology: Current Status and Possible Impacts on Systemic and Local Treatment;International Journal of Molecular Sciences;2024-07-15

4. Treatment options in the advanced and recurrent setting for endometrial cancer: an update;Expert Review of Anticancer Therapy;2024-06-24

5. The evolving role of immune checkpoint inhibitors in cervical and endometrial cancer;Cancer Drug Resistance;2024-06-11